From science to stock exchange, SCIENTEX is a healthcare focused corporate & bus dev firm

SCIENTEX- SIRET : 490128675 - 5 avenue d’ouessant 44500 La Baule - FRANCE Mobile : +33 (0)6 45 52 35 40 - tm@scientex.eu– Skype : timotheemuller - https://www.linkedin.com/in/timotheemuller/

OUR CORE SUPPORTS DEDICATED TO HEALTHCARE SMEs COVERING CBO & CFO FUNCTIONS

BRING CASH : through R&D partnering & BD&L deals + through financing deals (fundraising, IPO, IR) REDUCE COSTS : more value-added, more track record, more tools, more networks all included.

Created in 2006, SCIENTEX® is a healthcare dedicated, advisory & transition management firm, focused on supporting biopharma SMEs, by leveraging +20 years of track

record & assets of its 2 associates. We ‘ve built 4 services & products in order to cover their corporate needs :

4 PRODUCTS AND SERVICES DEDICATED TO BIOTECH & PHARMA SMEs

SCIENTEX® = advisory & transition management covering CFO & CBO functions BIOTECHNEWS® = corporate & PR news services covering the life sciences market BIOFOCUS® = data analysis & market intelligence databases focused on healthcare market BIOPHARMACAPITAL® = fundraising & Investor Relation support for biotech & pharma SMEs

In other words, the 2 associates of SCIENTEX will be happy to act as an executive sherpa for C-level manager and support your growth & projects by :

raising capital from investors, wealthy individuals or going public & managing IR

structuring R&D partnering and in&out licensing deals

managing M&A opportunities on sell & buy side

boosting marketing & sales operations

advising on strategic intelligence, branding, communications & investor relations

1. SCIENTEX received 6 business & corporate awards

● APRIL 2016 : Most Efficient Healthcare Business Boutique in Europe, by ACQUISITION INTERNATIONAL, the voice of corporate finance

● OCTOBER 2016 for its excellence in corporate affairs support - France, by WEALTH& FINANCE international

● JANUARY 2017 as European Life Sciences Business Boutique of the Year in Corporate LiveWire’s 2017 Innovation & Excellence Awards.

● FEBRUARY 2017 as Most engaged & results driven Contract Business Development Organization in Europe by ACQUISITION INTERNATIONAL

● MARCH 2017 for its excellence in international business management, by WEALTH& FINANCE international

● MARCH 2018 Best business development company in Europe, by ACQUISITION INTERNATIONAL, the voice of corporate finance

2. TRACK RECORD : by Scientex’s associates since 1999:

+100 deals = sell & buy side, including 5 IPOs, 9 M&A, 8 out-licensing, 29 commercial , 28 financing

+30 missions during the last 10 years generating +2,5M€ of net fees for SCIENTEX.

26 board member position since 1999 to date.

+600 BP sourced & screened as VC & venture partner, 17 investments in life sciences

3. NETWORK : of Scientex’s associates : +39 000 biopharma dealmaker network regularly updated from attendees from all major partnering events : DCAT,

Bioeurope, BIO USA, Biotechshowcase, EuroPLX, Pharmavenue, Bionetwork summit, Biopharma America, CPHI, Bioeurope Spring, JPMorgan Healthcare….

4. BIOPHARMACAPITAL® : IR services based on +6000 EU private & public investor network (BA, institutional & wealth investors & individuals) : thanks to 10

years of private equity background and executive board member position of an Euronext listed specialty pharma (IPO, 2 follow on & Investor Relations) : 250 one to one

and 1 to few investors, familly offices and wealth managers meetings per year, mainly in Europe & some in USA since 2014.

5. BIOFOCUS® : A >20Go, healthcare focused market intelligence database inside Scientex : + 21 000 market studies = company coverage + full disease

overview + detailed pipeline + products forecast + epidemiology overview + deals + treatment trees + stakeholder & KOL insights, trends & outlook + operation database

(model for SOP, by laws, SPA, IND & IMPD, NPV model...). Our databases, sourced and updated weekly from the most well known market intelligence providers &

investment banks; will help you to build your forecast , positioning and competition landscape.

6. BIOTECHNEWS® : save costs thanks to BIOTECHNEWS, our life sciences press release & corporate communication services. A broad audience access to 4

millions of professionals (+24 000 contacts & member of 100 healthcare & investors newsgroups on Linkedin).

7. CASE STUDY with CROSSJECT : Ex pharma research scientist during the 90s on CNS & diabete mellitus, ex venture capitalist during the 2000s having invested

in +16 biotech and since 2006, having performed +30 advisory & transition management missions for biotech & pharma & investments companies through my company

Scientex from 2006 to 2017 generating +2,5M€ of net fees, SCIENTEX recently realized a dual track mission for Crossject, strongly supporting its founding CEO by covering

CFO&CBO functions. Tim was acting as Chief Business Officer and member of the Executive Board of CROSSJECT during these last 6 years (2012-18) of transformation

from a private start-up medtech company presenting a €2M valuation in 2012 into an Euronext listed specialty pharmaceutical company (IPO was in feb 2014 valued €65M

& €17M raised) including leading its private equity refinancing in 2013 ($ 6M) and its IPO, while driving business development & licensing (8 term sheets signed & several

deals fully negotiated) & managing M&A opportunities. I was fully dedicated and full time, home office based for Crossject since i was travelling around 40% max of my

time. As an example, during 2016, Tim performed around 300 commercial meetings on a ww basis and met 250 investors. Complementary, thanks to its broad healthcare

database, SCIENTEX has also been mandated to screen the 907 injectable drugs in order to double the R&D portfolio : 200 injectables were ZENEO compatible and 5

products have been selected and highlighted by SCIENTEX supporting the 6,7M euros grant from BPI/PIAVE

In term of BD&L activities, we are almost 3 times more productive in meeting with industrials & investors ● ranked 1st at BIO USA june 2016 by the organizers thanks to +77 scheduled meetings where only 15% of the 6322 other partnering delegates reached to have +25

meetings,

● ranked 5th at BIOEUROPE 2016 with 50 1to1 meetings in 2,5 days, while the 3647 delegates reached to have an average of 12 meetings/delegates

8. OUR CLIENTS 9 2 C-LEVEL ASSOCIATES : see founder’s resume

10 REDUCE PAYROLLS & GAIN FLEXIBILITY: SCIENTEX is a more flexible, lower cost and stronger support solution compared to full time employee. We can

work with you shared up to 2 clients max in parallel or full time fully dedicated, depending your needs. We are covering and supporting CBO & CFO functions

Tim Muller - - tm@scientex.eu 48 years , married, 3 children, French native, Tel: +33. 645.523. 540

Home & Office : 5 avenue d’ouessant 44500 La Baule - FRANCE

http://www.scientex.eu – https://www.linkedin.com/in/timotheemuller/

SNAPSHOT :covering CFO + CBO functions for healthcare SMEs =

Financing+IPO+IR+M&A+R&D partnering + BD&L+ corporate strategy & communications After a first R&D experience on radiopharmaceuticals at AREVA R&D (CEA/IPSN) in 1993, Tim

worked as a R&D pharmacochemist for the pharmaceutical industry (SERVIER) during 5 years on

diabetes mellitus & CNS. In 99, Tim joined the private equity industry (CDC enterprises & Sofimac

Partners) investing in 17 healthcare companies (6 were acquired by industrials & 5 IPOs) from his

600 deal flow proactively sourced & screened. In 2006, Tim founded SCIENTEX, a healthcare

dedicated advisory & transition management firm focused on business & corporate development,

M&A (buy & sell side), while he was advising wealthy individuals on VIX trading & working with

primary & secondary private equity funds. Since 2008, Tim led the business development activities

of several biotech & pharma as head of M&A for Pharma Omnium, VP Bus Dev of Cytune Pharma &

Tetrahedron. In 2012, Tim joined CROSSJECT in 2012 during its restart in order to transform its

ZENEO based medtech business model presenting a 2M€ valuation into an Euronext listed specialty

pharma (IPO in feb 14 valued 65M€). After the successful completion of a 472M$ ww licensing deal

on ZENEO epinephrin; Tim, acting as CBO & member of the executive board, led & drove the $6M

refinancing closed in june 2013 while managing M&A opportunities. Tim initiated & engaged the IPO

process, successfully oversubscribed 4,4 x in feb 2014 & negotiated 2 out-licensing deals for ZENEO

MTX covering China valuated 360M€ including 25% royalties & covering Indian regions including royalties

between 20% to 40%. For CROSSJECT, Tim was fully dedicated and full time, home based with 40%

of ww travel and negotiated 8 term sheets. During 2016, Tim performed around 300 commercial

meetings on a ww basis and met 250 investors. Complementary, thanks to its broad healthcare

database, SCIENTEX has also been mandated to screen the 907 injectable drugs in order to double

CROSSJECT’s R&D portfolio : 200 injectables were ZENEO compatibles and 5 products have been

selected and highlighted by SCIENTEX supporting the 6,7M euros grant from BPI/PIAVE. Globally,

Tim has been involved in +100 corporate & business transactions, on sell & buy side, including 5

IPOs, 9 M&A, 8 out-licensing deals, 29 commercial deals, 28 financing deals with a worldwide

coverage. Tim was board member for 26 companies and realized through SCIENTEX +30 missions in

10 years generating +2,5M€ of net fees

http://www.scientex.eu/app/download/8649510/Tim+Muller++Scientex+full+package.pdf

P R O F E S S I O N A L E X P E R I E N C E 06/2012 – 03/2018 CROSSJECT: needle free self injectable drugs DIJON

Chief Business Officer & Executive Board Member / pharmaceuticals

11/2013 – 02/2018 KYMOS : analytical & clinical CRO BARCELONA Head of business development (FR, LUX, BEL, CH) through a mandate with Scientex

09/2011 – 03/2013 TETRAHEDRON : healthcare nutrition & cosmetics PARIS

Vice President corporate & business development through a mandate with Scientex

2010 7 months CYTUNE PHARMA : biotech NANTES Vice President corporate & business development through a mandate with Scientex

07/2008 – 05/2012 PHARMA OMNIUM INTERNATIONAL : pharma PARIS Director commercial & partnership development (M&A) through a mandate with Scientex

02/2008 – 05/2010 GO CAPITAL : private equity RENNES Venture Partner life sciences through a mandate with Scientex

09/2006 – 11/2008 SCOTTISH ENTERPRISES: investment governt body GLASGOW Senior Business Development Consultant, healthcare & finance, southern EMEA through a

mandate with Scientex

05/2006 - date SCIENTEX : advisory & transition management LA BAULE Founding CEO / healthcare focused corporate & business development firm

● M&A MISSIONS : BIOFORTIS, NICOX

● BUSDEV & LICENSING and R&D PARTNERING MISSIONS : ELICITYL, DISCOVERX Corp,

● STRATEGIC AUDIT : PHERECYDES Pharma, HEMARINA, METAFORA BIO∑, MUTABILIS

● R&D MISSIONS : CROSSJECT

● FUNDRAISING MISSIONS : CROSSJECT, ELICITYL

● PRIVATE EQUITY ADVISOR : ARCIS, DAHLIA Partners, Normandie Part, VFCFAR

● SEED ENTREPRENEUR : MYELOMAX, INSERM, ATLANPOLE

03/2004 - 09/2006 CDC ENTREPRISES (= BPI FRANCE) : private equity PARIS Partner healthcare / Venture & growth capital

03/1999 – 03/2004 SOFIMAC PARTNERS : private equity CLERMONT-FERRAND General Partner life sciences / venture & growth capital & small LBO

09/1993 – 08/1998 LABORATOIRES SERVIER : pharmaceuticals COURBEVOIE Senior research scientist on diabete mellitus and CNS

1993 8 months AREVA/CEA : radiopharmaceuticals SACLAY Project Engineer developing an analytical method for radioactive uranium complex

E D U C A T I O N

2006 Master in Finance Pantheon/Sorbonne Graduate Business School/IAE, Paris

1998 Master in General Management RIS Faculty of Pharmacy/ISSBA, Angers Univ

1995 PhD in Healthcare & Life Sciences Faculty of Pharmacy, Nantes Univ

1992 Master certificate in pharmaceuticals Faculty of Pharmacy / ICPAL, Lille Univ

2 6 B O A R D M E M B E R P O S I T I O N S s i n c e 1 9 9 9 Vice President of the supervisory board of: ● Avidis SA (Vice President, 1999-2004, seed the spin off from MRC labs in Cambridge,now Imaxio 1999-

2004 and sold to the familly office Edulis),

● Bionisis SA (Vice President, 99- 04),

● Cellpep SA (Vice President, 99-04, now AMBRILIA, listed on Toronto Stock Exchange through a RTO ),

Member of the board of Directors of :

● Trophos SA (1999-2004, sold to Roche 470Meuros),

● OPI SA (99-04, sold to EUSA PHARMA 107Meuros, best venture exit in 2010),

● Txcell SA (2004-2006, co-lead the 10M€ serie A, 2004-2006 listed on Euronext),

● Metabolic Explorer SA (listed, best venture exit price in 2008),

● Crossject SA (april 2013-to march 2017, listed on Euronext),

● Integragen SA (co-lead the pre-IPO serie D, listed on Euronext)

● Bioacess SA, (sold to Biorad, IRR 3x the investment)

● Genolife SA (sold to Cambrex) ● Proteus SA (99-2004, sold to PCAS),

● Digestar SA, failed ● Nucleica SA (99-04), (bankrupt)

● Entomed SA (2005-2006) ● Biomethodes SA (2005-2006)

● Scientex SARL (2006 to date) ● Scimul SCI (2010 to date)

Portfolio management as Censor :

● Scynexis Inc (USA, now Listed on Nasdaq), ● Saphir GmBH (Germany), ● PIL SA, ● BMD SA,

● Cyclopharma SA, ● LMD SA (bankrupt), ● Synt:em SA (bankrupt) , ● Greentech SA.